Rhythm Biosciences’ antibodies pass latest round of tests
Rhythm Biosciences (ASX:RHY), developer of the ColoSTATTM blood test targeting the accurate and early detection of colorectal cancer, has completed the first phase of development of two new antibody reagents.
Four independent mixed monoclonal antibody preparations have now been identified that pass all three preliminary screening tests. This work was completed under RHY’s research contract with CSIRO on time and on budget.
The results of Phase 1 will now trigger the next phase of key reagent development, which involves the cloning of cells that produce the “desired antibody specificities”— separating them from other cells producing other products.
This next cloning step is crucial to ensuring that RHY has a reliable, long-term source of these key reagents, and establishes monoclonal antibody-producing cell lines. Following that, the cell lines will undergo “detailed characterisation, expansion and biobanking”.
Monoclonal antibodies produced by the cell lines will be characterised in detail, in order to identify which is likely to be most suitable for use in RHY’s ColoSTATTM. The company expects the cloning steps to be completed by late June 2018, following which will be the antibody production phase.
As always, it should be noted that RHY is an early stage play and anything can happen, so seek professional financial advice if considering this stock for your portfolio.
More about ColoSTATTM
RHY’s ColoSTATTM uses antibodies to measure the levels of several particular proteins in the blood, which have been shown to vary in the presence of absence of colorectal cancer. The concentration values are then combined using a proprietary algorithm, and this process provides an indication of cancer risk. A returned result above a certain threshold will be an indicator that a patient should progress to a colonoscopy for further investigation.
RHY Managing Director Dr Trevor Lockett commented on today’s news: “Rhythm’s key focus for the coming months is to secure our own antibodies and target proteins to give us control of the supply, quality and cost of these key reagents.
“Confirmation that we have antibodies that pass all three pre-screening tests in four of our mixed antibody populations is excellent news for our product development program. We expect to know if this next, all important cloning process has been successful by late June 2018.”